about
Nuclear transport, oxidative stress, and neurodegenerationNuclear factor erythroid 2-related factor 2 facilitates neuronal glutathione synthesis by upregulating neuronal excitatory amino acid transporter 3 expression.Cellular interplay between neurons and glia: toward a comprehensive mechanism for excitotoxic neuronal loss in neurodegenerationmicroRNAs: Emerging Targets Regulating Oxidative Stress in the Models of Parkinson's DiseaseRedox Imbalance and Viral Infections in Neurodegenerative DiseasesRole of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanismAn overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levelsMitochondrial Dysfunction Contributes to the Pathogenesis of Alzheimer's DiseaseThe Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseasesThe role of free radicals in the aging brain and Parkinson's Disease: convergence and parallelismOxidative stress responses and NRF2 in human leukaemiaMitochondrial quality control: decommissioning power plants in neurodegenerative diseasesImpaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtinBinding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complexPotential role of olive oil phenolic compounds in the prevention of neurodegenerative diseasesDual TNFα-induced effects on NRF2 mediated antioxidant defence in astrocyte-rich cultures: role of protein kinase activationActivated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3βStress-activated cap'n'collar transcription factors in aging and human diseaseCACUL1/CAC1 Regulates the Antioxidant Response by Stabilizing Nrf2Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agentsMechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid estersTime-dependent effects of systemic lipopolysaccharide injection on regulators of antioxidant defence Nrf2 and PGC-1α in the neonatal rat brainEmerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotectionNRF2-regulation in brain health and disease: implication of cerebral inflammationSalvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease modelsThe status of Nrf2-based therapeutics: current perspectives and future prospectsTherapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease modelsModulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseasesAltered transcription factor trafficking in oxidatively-stressed neuronal cells.Antroquinonol Lowers Brain Amyloid-β Levels and Improves Spatial Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease.Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease.Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease.Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease.The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.Genetic Variations and mRNA Expression of NRF2 in Parkinson's Disease.Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity.Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's diseaseHydrogen peroxide responsive miR153 targets Nrf2/ARE cytoprotection in paraquat induced dopaminergic neurotoxicity.Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease
P2860
Q24624357-019E8F1D-5D78-4DBD-8BD2-138B87845E7EQ24631707-C9BF001E-EBBD-4D78-9A96-84AAD8427A8DQ24654460-2C21E302-64A5-481F-8C52-9A04852191D8Q26738440-4616EA2D-BCBB-4A1F-B29C-82E80F5609E1Q26750630-3EDBF6B5-71E8-4069-B3B7-99E775BCF784Q26751266-7FC8CB34-7BDB-42D9-AC3F-1E2CE5ADDA69Q26751302-400DF395-87C1-40B7-9129-495D05B14AB7Q26801929-0960121B-5F1A-4BC9-AC70-C999C77EECD7Q26822972-87FD2D79-AADF-41D9-BF0B-BEA8ACB2B456Q26852148-913CA1D6-1ABB-4386-B64B-63A9DBFF4903Q26864239-A65D9640-6F06-4567-BA53-75F55787C7F3Q27009213-1D70078B-000F-4448-AEEE-8B633632C29CQ27312215-D082AD2D-0B05-4F2E-A960-FA1CCBB4B88DQ27689053-10ADCAA7-49DE-4627-BDC7-A2A478C9FDFFQ28259010-FA57F3AF-2D02-4087-908B-0E10602AB39FQ28383476-DD0A6ADB-BF1B-46AF-B526-77C5B1E5510DQ28383951-41AF11ED-942C-4D79-8D8B-929B00561530Q28384783-99D72CCA-50C5-42CD-A07A-A8908F7965E0Q28384997-07EA33DD-5ED7-4941-87AB-3EAE34DF34DBQ28386244-02929A5D-459F-4FF8-929F-3FFF2662AA99Q28389828-E1931700-0D7D-4258-AF9B-6B1F24430AE1Q28390052-D9EEEA06-1799-4742-9CB8-142C0B441DCFQ28396785-DCD112A0-5817-4AD9-8188-D7AC83328243Q28397785-7AA48157-DB7D-411B-817E-82D4CE7FB0AFQ28540349-45D2C0E8-F528-4DD8-825A-05BBA4ECA557Q28818264-0EC95709-C86F-455A-ABF7-C3097660D959Q28818353-E73008AC-9872-43CC-8275-CE46F03B6D86Q29247921-77BAB43D-8FD2-4152-AEEC-64A299285EC8Q30419484-27EB76FB-12D9-4E46-A86D-C1D1CB1FD6AEQ30668645-2602076A-2957-4343-A43C-2735872E1506Q30847085-27B5821B-A96E-40B7-9982-2A1D4AF768E1Q33536124-D60AC1B5-FBD0-4356-85D3-ED866778AD10Q33614523-C5C687EC-46B2-4600-891B-4182A2C2589CQ33659621-065958E6-101D-4A86-BF1D-00FAF82F7E07Q33692840-199CB745-C859-4CCF-8ACA-10A8676E64A6Q33800053-C70FE194-B4F5-43E1-B6A2-73C9EA038088Q33912442-AEC9C536-355C-41CF-A920-1401071C01BAQ33958143-FB88664A-5F9D-4567-9939-91D31E8BC490Q34004577-7D1CFA37-8E7B-4585-8A1D-FB8624DD4C08Q34043950-1CC4C2B2-D94C-4051-ACBB-0033E278FBC3
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Expression of Nrf2 in neurodegenerative diseases
@ast
Expression of Nrf2 in neurodegenerative diseases
@en
type
label
Expression of Nrf2 in neurodegenerative diseases
@ast
Expression of Nrf2 in neurodegenerative diseases
@en
prefLabel
Expression of Nrf2 in neurodegenerative diseases
@ast
Expression of Nrf2 in neurodegenerative diseases
@en
P2093
P2860
P1476
Expression of Nrf2 in neurodegenerative diseases
@en
P2093
Charleen T Chu
Charles A Glass
Chenere P Ramsey
Gillian P Ritson
Kathryn A Lindl
Kelly L Jordan-Sciutto
Luis A Chia
Marshall B Montgomery
Ronald L Hamilton
P2860
P356
10.1097/NEN.0B013E31802D6DA9
P577
2007-01-01T00:00:00Z